All In Biotech

NDA 020255 · Baxter Hlthcare

Dobutamine Hydrochloride In Dextrose 5% In Plastic Container

Dobutamine Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Sep 8, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1993

Sep 27, 1993

Approved uses

1

Original approval plus efficacy supplements

Registered trials

80

14 Phase 3, 7 recruiting

FAERS reports

1,297

1,252 serious, 543 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 30, 2024.

INDICATIONS & USAGE Dobutamine Hydrochloride in 5% Dextrose Injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 27, 1993 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 400MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 100MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 50MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER · DOBUTAMINE HYDROCHLORIDE EQ 200MG BASE/100ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Dobutamine" as an intervention, any sponsor and status, largest first.

All 80 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death271
  • stress179
  • off label use162
  • sepsis155
  • multiple organ dysfunction syndrome148
  • condition aggravated145
  • general physical health deterioration140
  • drug ineffective133
  • hyponatraemia132
  • cardiogenic shock129
  • nausea124
  • ascites120

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20051
200711
200818
200914
201029
2011106
201222
201335
201448
2015196
201629
201785
201895
201924
202027
202188
202294
2023151
202475
202577
202664

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02).

  • Current · updated Nov 18, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02).

  • Current · updated Nov 18, 2026

    Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,229 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.